Opus Genetics: Asymmetric Upside With LCA5 And BEST1 [Seeking Alpha]
Opus Genetics, Inc. (IRD)
Company Research
Source: Seeking Alpha
Its lead candidate is OPGx-LCA5, which is moving into Phase 3 enrollment. Interestingly, OPGx-LCA5's Phase 1/2 showed encouraging safety and functional vision improvements and already has important FDA designations. Similarly, OPGx-BEST1 is an early-stage but promising program with supportive preclinical signals. Its 2026 readouts could be a meaningful catalyst. In my view, IRD's current valuation offers an attractive high-risk, high-reward bet at these levels, contingent on IRD succeeding with either of those two candidates. bymuratdeniz/E+ via Getty Images Opus Genetics, Inc. ( IRD ) is a gene-therapy developer focused on inherited retinal diseases (IRDs). The company uses adeno-associated virus (AAV) and aims for a one-dose treatment for gene augmentation to repair retinal structure. Its lead program is OPGx-LCA5 for Leber This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and
Show less
Read more
Impact Snapshot
Event Time:
IRD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRD alerts
High impacting Opus Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
IRD
News
- Update: Opus Genetics Shares Rise After Announcement of $25 Million Private Placement [Yahoo! Finance]Yahoo! Finance
- Opus Genetics Announces $25 Million Private PlacementGlobeNewswire
- Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.MarketBeat
- Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026GlobeNewswire
- Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.MarketBeat
IRD
Sec Filings
- 2/19/26 - Form 8-K
- 2/17/26 - Form 4
- 2/17/26 - Form SCHEDULE
- IRD's page on the SEC website